{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:25:35Z","timestamp":1766010335333,"version":"3.48.0"},"posted":{"date-parts":[[2025,6,17]]},"group-title":"In Review","reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,6,11]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background:<\/bold>\n                  Erythropoietin (EPO) is a potential therapeutic for Alzheimer's disease (AD), but has limited brain penetration, requiring high systemic doses that lead to hematopoietic side effects. To overcome this, EPO was conjugated with a transferrin receptor monoclonal antibody (TfRMAb) to enhance blood-brain barrier transport. This study assessed the pharmacokinetics (PK), safety, and efficacy of this modified EPO after repeated dosing in mice.\n                  <bold>Methods:<\/bold>\n                  For the PK and safety study, a multidose design was employed with 10-week-old C57 male mice (n=4-5\/dose) receiving low (1 mg\/kg), mid (3 and 6 mg\/kg), or high (20 mg\/kg) doses SQ for 4 weeks, aimed to evaluate the dose-dependent plasma concentrations and biodistribution, and metabolic and hematologic safety of the modified EPO. The dose that resulted in the highest safety and sustained plasma exposure was then dosed SQ to 5.5-month-old male APP\n                  <sub>SAA<\/sub>\n                  KI mice (n=6) for 14 weeks. Controls included vehicle-treated APP\n                  <sub>SAA<\/sub>\n                  KI and APP wild-type mice (n=4\u20135\/group). The effect of modified EPO on A\u03b2 load by immunoassays and spatial memory via the Y-maze test were assessed.\n                  <bold>Results:<\/bold>\n                  The 1 mg\/kg dose showed no adverse effects and sustained brain and plasma exposure following repeated dosing, making it suitable for longitudinal treatment. Mid and high doses reduced plasma and brain exposure, and altered hematocrit, TfR expression, and spleen weight; changes that were largely reversible upon treatment cessation. Reduced plasma exposure at mid and high doses was not completely explained by increased TfR expression, anti-drug antibodies, tissue sequestration, or EPO receptor expression. Subsequently, 5.5-month-old APP\n                  <sub>SAA<\/sub>\n                  KI mice received 1 mg\/kg TfRMAb-EPO SQ for 14 weeks. Modified EPO significantly reduced brain A\u03b2 load (70\u201380%, p&lt;0.001) and aggregated A\u03b2 (p&lt;0.05), and improved spatial memory, indicated by a higher discrimination index in the Y maze test (p&lt;0.05).\n                  <bold>Conclusions:<\/bold>\n                  With the advancement of TfRMAb-based therapeutics into clinical trials for AD, these findings are particularly significant. They offer essential preclinical data to guide dose optimization in longitudinal studies using TfRMAb-based therapeutics, specifically modified-EPO, and show the robust therapeutic potential of low-dose brain-penetrating EPO in the APP\n                  <sub>SAA<\/sub>\n                  KI AD mouse model.\n                <\/p>","DOI":"10.21203\/rs.3.rs-6874797\/v1","type":"posted-content","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:51:38Z","timestamp":1750135898000},"source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal pharmacokinetic and safety studies for dose optimization of a brain- penetrating erythropoietin for Alzheimer\u2019s disease"],"prefix":"10.21203","author":[{"given":"Rudy","family":"Chang#","sequence":"first","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devaraj V.","family":"Chandrashekar#","sequence":"additional","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Chuli","family":"Roules","sequence":"additional","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataraj","family":"Jagadeesan","sequence":"additional","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adenike","family":"Oyegbesan","sequence":"additional","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayk","family":"Davtyan","sequence":"additional","affiliation":[{"name":"University of California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachita K.","family":"Sumbria","sequence":"additional","affiliation":[{"name":"Chapman University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"DeTure MA","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14(1):32.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang J","year":"2024","unstructured":"Zhang J, et al. Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12017-019-08524-y","article-title":"The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease","volume":"21","author":"Sun J","year":"2019","unstructured":"Sun J, et al. The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease. Neuromolecular Med. 2019;21(1):12\u201324.","journal-title":"Neuromolecular Med"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.109.165092","article-title":"Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse","volume":"333","author":"Boado RJ","year":"2010","unstructured":"Boado RJ, et al. Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. J Pharmacol Exp Ther. 2010;333(3):961\u20139.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Pt 1","key":"ref5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1113\/jphysiol.2006.122689","article-title":"Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume","volume":"578","author":"Lundby C","year":"2007","unstructured":"Lundby C, et al. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol. 2007;578(Pt 1):309\u201314.","journal-title":"J Physiol"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1517\/13543784.2010.517954","article-title":"Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!","volume":"19","author":"Lapchak PA","year":"2010","unstructured":"Lapchak PA. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! Expert Opin Investig Drugs. 2010;19(10):1179\u201386.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/mp1001763","article-title":"Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse","volume":"7","author":"Zhou QH","year":"2010","unstructured":"Zhou QH, et al. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Mol Pharm. 2010;7(6):2148\u201355.","journal-title":"Mol Pharm"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.trci.2019.09.003","article-title":"Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP\/PS1 mice","volume":"5","author":"Sun J","year":"2019","unstructured":"Sun J, et al. Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP\/PS1 mice. Alzheimers Dement (N Y). 2019;5:627\u201336.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1021\/acs.molpharmaceut.8b00594","article-title":"Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease","volume":"15","author":"Chang R","year":"2018","unstructured":"Chang R, et al. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. Mol Pharm. 2018;15(11):4963\u201373.","journal-title":"Mol Pharm"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-022-00547-7","article-title":"Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia","volume":"17","author":"Xia D","year":"2022","unstructured":"Xia D, et al. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegener. 2022;17(1):41.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090852","article-title":"Acute and Chronic Dosing of a High-Affinity Rat\/Mouse Chimeric Transferrin Receptor Antibody in Mice","volume":"12","author":"Castellanos DM","year":"2020","unstructured":"Castellanos DM et al. Acute and Chronic Dosing of a High-Affinity Rat\/Mouse Chimeric Transferrin Receptor Antibody in Mice. Pharmaceutics, 2020. 12(9).","journal-title":"Pharmaceutics"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.3390\/pharmaceutics14102200","article-title":"Efficacy and Safety of a Brain-Penetrant Biologic TNF-\u03b1 Inhibitor in Aged APP\/PS1 Mice","volume":"14","author":"Ou W","year":"2022","unstructured":"Ou W, et al. Efficacy and Safety of a Brain-Penetrant Biologic TNF-\u03b1 Inhibitor in Aged APP\/PS1 Mice. Pharmaceutics. 2022;14(10):2200.","journal-title":"Pharmaceutics"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jneumeth.2014.02.001","article-title":"Burrowing and nest building behavior as indicators of well-being in mice","volume":"234","author":"Jirkof P","year":"2014","unstructured":"Jirkof P. Burrowing and nest building behavior as indicators of well-being in mice. J Neurosci Methods. 2014;234:139\u201346.","journal-title":"J Neurosci Methods"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"114707","DOI":"10.1016\/j.bbr.2023.114707","article-title":"Apathy-like behaviour in tau mouse models of Alzheimer's disease and frontotemporal dementia","volume":"456","author":"Robinson L","year":"2024","unstructured":"Robinson L, et al. Apathy-like behaviour in tau mouse models of Alzheimer's disease and frontotemporal dementia. Behav Brain Res. 2024;456:114707.","journal-title":"Behav Brain Res"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12967-024-05008-x","article-title":"Modulation of hippocampal protein expression by a brain penetrant biologic TNF-\u03b1 inhibitor in the 3xTg Alzheimer's disease mice","volume":"22","author":"Jagadeesan N","year":"2024","unstructured":"Jagadeesan N, et al. Modulation of hippocampal protein expression by a brain penetrant biologic TNF-\u03b1 inhibitor in the 3xTg Alzheimer's disease mice. J Transl Med. 2024;22(1):291.","journal-title":"J Transl Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"101584","DOI":"10.1016\/j.mex.2021.101584","article-title":"The concentration of brain homogenates with the Amicon Ultra Centrifugal filters","volume":"8","author":"Yang J","year":"2021","unstructured":"Yang J, Sumbria RK. The concentration of brain homogenates with the Amicon Ultra Centrifugal filters. MethodsX. 2021;8:101584.","journal-title":"MethodsX"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1021\/acs.molpharmaceut.9b00369","article-title":"Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice","volume":"16","author":"Sun J","year":"2019","unstructured":"Sun J, et al. Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice. Mol Pharm. 2019;16(8):3534\u201343.","journal-title":"Mol Pharm"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1208\/s12248-022-00728-8","article-title":"Comparison of Titer and Signal to Noise (S\/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium","volume":"24","author":"Starcevic Manning M","year":"2022","unstructured":"Starcevic Manning M, et al. Comparison of Titer and Signal to Noise (S\/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium. AAPS J. 2022;24(4):81.","journal-title":"AAPS J"},{"key":"ref19","first-page":"13","article-title":"Modulation of hepatic amyloid precursor protein and lipoprotein receptor-related protein 1 by chronic alcohol intake: Potential link between liver steatosis and amyloid-\u03b2","author":"Garcia J","year":"2022","unstructured":"Garcia J et al. Modulation of hepatic amyloid precursor protein and lipoprotein receptor-related protein 1 by chronic alcohol intake: Potential link between liver steatosis and amyloid-\u03b2. Front Physiol, 2022. 13.","journal-title":"Front Physiol"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13195-023-01236-3","article-title":"Long-term effects of immunotherapy with a brain penetrating Abeta antibody in a mouse model of Alzheimer's disease","volume":"15","author":"Gustavsson T","year":"2023","unstructured":"Gustavsson T, et al. Long-term effects of immunotherapy with a brain penetrating Abeta antibody in a mouse model of Alzheimer's disease. Alzheimers Res Ther. 2023;15(1):90.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1021\/acs.molpharmaceut.8b00730","article-title":"Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor","volume":"15","author":"Pardridge WM","year":"2018","unstructured":"Pardridge WM, et al. Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor. Mol Pharm. 2018;15(11):5207\u201316.","journal-title":"Mol Pharm"},{"key":"ref22","first-page":"100758","article-title":"Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II","volume":"27","author":"Yamamoto R","year":"2021","unstructured":"Yamamoto R, et al. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Mol Genet Metab Rep. 2021;27:100758.","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1124\/dmd.111.038349","article-title":"Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein","volume":"39","author":"Zhou QH","year":"2011","unstructured":"Zhou QH, et al. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab Dispos. 2011;39(7):1149\u201354.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12974-021-02332-7","article-title":"Biologic TNF-alpha inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy","volume":"18","author":"Ou W","year":"2021","unstructured":"Ou W, et al. Biologic TNF-alpha inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy. J Neuroinflammation. 2021;18(1):312.","journal-title":"J Neuroinflammation"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","article-title":"Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil","volume":"29","author":"Giugliani R","year":"2021","unstructured":"Giugliani R, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther. 2021;29(7):2378\u201386.","journal-title":"Mol Ther"},{"issue":"261","key":"ref26","first-page":"261ra154","article-title":"Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates","volume":"6","author":"Yu YJ","year":"2014","unstructured":"Yu YJ, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6(261):261ra154.","journal-title":"Sci Transl Med"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly N","year":"2014","unstructured":"Bien-Ly N, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211(2):233\u201344.","journal-title":"J Exp Med"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/acs.molpharmaceut.7b00200","article-title":"Blood-Brain Barrier Penetrating Biologic TNF-alpha Inhibitor for Alzheimer's Disease","volume":"14","author":"Chang R","year":"2017","unstructured":"Chang R, et al. Blood-Brain Barrier Penetrating Biologic TNF-alpha Inhibitor for Alzheimer's Disease. Mol Pharm. 2017;14(7):2340\u20139.","journal-title":"Mol Pharm"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3233\/JAD-141389","article-title":"Memory Improvement in the A\u03b2PP\/PS1 Mouse Model of Familial Alzheimer\u2019s Disease Induced by Carbamylated-Erythropoietin is Accompanied by Modulation of Synaptic Genes","volume":"45","author":"Armand-Ug\u00f3n M","year":"2015","unstructured":"Armand-Ug\u00f3n M, et al. Memory Improvement in the A\u03b2PP\/PS1 Mouse Model of Familial Alzheimer\u2019s Disease Induced by Carbamylated-Erythropoietin is Accompanied by Modulation of Synaptic Genes. J Alzheimers Dis. 2015;45(2):407\u201321.","journal-title":"J Alzheimers Dis"},{"issue":"183","key":"ref30","doi-asserted-by":"crossref","first-page":"183ra57","DOI":"10.1126\/scitranslmed.3005338","article-title":"Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier","volume":"5","author":"Couch JA","year":"2013","unstructured":"Couch JA, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med. 2013;5(183):183ra57.","journal-title":"Sci Transl Med"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1038\/s41598-025-89051-8","article-title":"Longitudinal characterization reveals behavioral impairments in aged APP knock in mouse models","volume":"15","author":"Blackmer-Raynolds L","year":"2025","unstructured":"Blackmer-Raynolds L, et al. Longitudinal characterization reveals behavioral impairments in aged APP knock in mouse models. Sci Rep. 2025;15(1):4631.","journal-title":"Sci Rep"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease","volume":"36","author":"Lord A","year":"2009","unstructured":"Lord A, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2009;36(3):425\u201334.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker S","year":"2015","unstructured":"Tucker S, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575\u201388.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrn1687","article-title":"Emerging biological roles for erythropoietin in the nervous system","volume":"6","author":"Brines M","year":"2005","unstructured":"Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6(6):484\u201394.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1471-4159.2005.03033.x","article-title":"Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor","volume":"93","author":"Viviani B","year":"2005","unstructured":"Viviani B, et al. Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. J Neurochem. 2005;93(2):412\u201321.","journal-title":"J Neurochem"},{"key":"ref36","first-page":"1","article-title":"A simple role for BDNF in learning and memory?","volume":"3","author":"Cunha C","year":"2010","unstructured":"Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory? Front Mol Neurosci. 2010;3:1.","journal-title":"Front Mol Neurosci"},{"year":"2017","author":"Tanila H","key":"ref37","unstructured":"Tanila H. The role of BDNF in Alzheimer's disease. Neurobiol Dis, 2017. 97(Pt B): pp. 114\u2013118."},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.dadm.2015.01.005","article-title":"Plasma BDNF levels associate with Pittsburgh compound B binding in the brain","volume":"1","author":"Hwang KS","year":"2015","unstructured":"Hwang KS, et al. Plasma BDNF levels associate with Pittsburgh compound B binding in the brain. Alzheimers Dement (Amst). 2015;1(2):187\u201393.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.biopsych.2007.01.002","article-title":"Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity","volume":"62","author":"Lang UE","year":"2007","unstructured":"Lang UE, et al. Correlation between serum brain-derived neurotrophic factor level and an in vivo marker of cortical integrity. Biol Psychiatry. 2007;62(5):530\u20135.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jnr.22227","article-title":"Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease","volume":"88","author":"Sultana R","year":"2010","unstructured":"Sultana R, Banks WA, Butterfield DA. Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease. J Neurosci Res. 2010;88(3):469\u201377.","journal-title":"J Neurosci Res"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s44319-024-00090-0","article-title":"Hyperfunction of post-synaptic density protein 95 promotes seizure response in early-stage abeta pathology","volume":"25","author":"Yook Y","year":"2024","unstructured":"Yook Y, et al. Hyperfunction of post-synaptic density protein 95 promotes seizure response in early-stage abeta pathology. EMBO Rep. 2024;25(3):1233\u201355.","journal-title":"EMBO Rep"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JAD-2008-15112","article-title":"Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein","volume":"15","author":"Leuba G","year":"2008","unstructured":"Leuba G, et al. Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J Alzheimers Dis. 2008;15(1):139\u201351.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel H","year":"2021","unstructured":"Hampel H, et al. The Amyloid-\u03b2 Pathway in Alzheimer\u2019s Disease. Mol Psychiatry. 2021;26(10):5481\u2013503.","journal-title":"Mol Psychiatry"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopha.2018.05.028","article-title":"Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Abeta expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study","volume":"104","author":"G V","year":"2018","unstructured":"G V, et al. Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Abeta expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study. Biomed Pharmacother. 2018;104:211\u201322.","journal-title":"Biomed Pharmacother"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Selkoe, D.J. and J. Hardy, The amyloid hypothesis of Alzheimer's disease at 25\u00a0years. EMBO Molecular Medicine, 2016. 8(6): pp. 595-608-608.","DOI":"10.15252\/emmm.201606210"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6874797\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6874797\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T22:20:46Z","timestamp":1766010046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-6874797\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":45,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-6874797\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.ijpx.2025.100459","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,6,17]]},"subtype":"preprint"}}